Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer’s disease
- 11 March 2009
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica
- Vol. 118 (3) , 381-389
Abstract
Although Alzheimer’s disease (AD) has been shown to be associated with a true primary optic neuropathy, the underlying pathophysiology of this disease and in particular the optic nerve disorder is still poorly understood. The receptor for advanced glycation end products (RAGE) has been implicated in the pathogenesis of AD by mediating the transport of plasma amyloid-β into the brain. Once ligated, RAGE can play a role in signal transduction, leading to amplification and perpetuation of inflammatory processes. As a key player in the reaction to CNS injury, astrocytes have been shown to associate with RAGE in a number of diseases, including AD. To investigate the role of RAGE and astrocytes in the pathogenesis of AD optic neuropathy, we conducted immunohistochemical studies to examine the presence of RAGE in donor eyes from patients with AD (n = 10) and controls (n = 3). Both qualitative observation and quantitative analyses using imaging software were used to document the extent of RAGE in the neural tissues. The intensity and extent of RAGE expression was more prominent in AD nerves compared to controls (P < 0.05). The RAGE immunoreactivity was observed in the microvasculature and in close proximity to astrocytic processes. While RAGE immunoreactivity increased with age, the increase was more precipitous in the AD group compared to the controls. The up-regulation of RAGE in the AD optic nerves indicates that RAGE may play a role in the pathophysiology of AD optic neuropathy.Keywords
This publication has 39 references indexed in Scilit:
- Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's diseaseBrain Research, 2008
- Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by β-amyloid peptide acting through receptor for advanced glycation end products (RAGE)Molecular and Cellular Neuroscience, 2005
- Neurovascular mechanisms of Alzheimer's neurodegenerationTrends in Neurosciences, 2005
- Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammationGlycobiology, 2005
- Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Aβ and RAGE peptidesNeurobiology of Aging, 2004
- RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brainNature Medicine, 2003
- The biology of the receptor for advanced glycation end products and its ligandsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2000
- Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer.Journal of Clinical Investigation, 1998
- RAGE and amyloid-β peptide neurotoxicity in Alzheimer's diseaseNature, 1996
- Optic-Nerve Degeneration in Alzheimer's DiseaseNew England Journal of Medicine, 1986